Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CRN09682 in SST2-Expressing Neuroendocrine Neoplasms and Solid Tumors
NCT07129252Phase 2Active, not recruiting
- Sponsor
- Crinetics Pharmaceuticals
- Start
- Nov 2025
- Primary completion
- Aug 2027
- Modality
- Metabolically Activated Prodrugs, Peptide-Drug Conjugates
- Countries
- 2
01
Overview
A Phase 2 trial of CRN09682 in Neuroendocrine neoplasm (NEN), Neuroendocrine Neoplasm (NEN), neuroendocrine carcinoma (NEC), solid tumor, sponsored by Crinetics Pharmaceuticals. Started Nov 2025; status: active, not recruiting.
02
Drugs
CRN09682
03
Conditions
Neuroendocrine neoplasm (NEN)Neuroendocrine Neoplasm (NEN)neuroendocrine carcinoma (NEC)solid tumor
Beyond the preview
Go deeper on NCT07129252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07129252.